Literature DB >> 12888375

Time trends and regional differences in registration, stage distribution, surgical management and survival of breast cancer in Denmark.

A R Jensena1, M Ewertz, S Cold, H H Storm, J Overgaard.   

Abstract

The aim of this study was to analyse time trends, stage at diagnosis, survival and registration of population-based cohorts of breast cancer patients in selected Danish counties (in total 2504) in 1986 and 1996-1997. In 1986, no differences in the extent of disease were observed between the counties. Patients from one county (Funen) had centralised surgery, significantly more lymph nodes removed and a better survival in the multivariate analysis. In 1996-1997, mammographical screening had been implemented in Funen, leading to a significantly better stage distribution, whereas stage remained unchanged in the other counties. In Funen, survival was significantly better than in the other counties in univariate, but not in multivariate analysis. Survival increased significantly with time only in Funen. Inclusion in clinical trials increased over time and the coverage of the database in the Danish Breast Cancer Cooperative Group (DBCG) was high. However, patients not notified in DBCG had, beside older age, also worse stage of disease distribution and less extensive surgery. A difference in survival was observed between the counties. In 1986, this may be explained by a centralised surgical system in one county, whereas in 1996-1997 improvements could be due to an early diagnosis and other as yet unknown factors. The DBCG database cannot be considered as representative of the Danish population of breast cancer patients.

Entities:  

Mesh:

Year:  2003        PMID: 12888375     DOI: 10.1016/s0959-8049(03)00377-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study.

Authors:  Thomas P Ahern; Lars Pedersen; Maja Tarp; Deirdre P Cronin-Fenton; Jens Peter Garne; Rebecca A Silliman; Henrik Toft Sørensen; Timothy L Lash
Journal:  J Natl Cancer Inst       Date:  2011-08-02       Impact factor: 13.506

2.  Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.

Authors:  Thomas P Ahern; Deirdre P Cronin-Fenton; Timothy L Lash; Henrik Toft Sørensen; Anne Gulbech Ording; Stephen J Hamilton-Dutoit; Ylva Hellberg
Journal:  Acta Oncol       Date:  2016-04-08       Impact factor: 4.089

3.  CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

Authors:  Timothy L Lash; Deirdre Cronin-Fenton; Thomas P Ahern; Carol L Rosenberg; Kathryn L Lunetta; Rebecca A Silliman; Jens Peter Garne; Henrik Toft Sørensen; Ylva Hellberg; Mariann Christensen; Lars Pedersen; Stephen Hamilton-Dutoit
Journal:  J Natl Cancer Inst       Date:  2011-02-15       Impact factor: 13.506

4.  The effect of 14-3-3ζ expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.

Authors:  Jake E Thistle; Ylva Hellberg; Kristina Mortensen; Stephen Hamilton-Dutoit; Anders Kjærsgaard; Deirdre Cronin-Fenton; Henrik Toft Sørensen; Timothy L Lash
Journal:  Breast Cancer Res Treat       Date:  2017-06-22       Impact factor: 4.872

5.  Glucocorticoid prescriptions and breast cancer recurrence: a Danish nationwide prospective cohort study.

Authors:  L W Lietzen; T Ahern; P Christiansen; A B Jensen; H T Sørensen; T L Lash; D P Cronin-Fenton
Journal:  Ann Oncol       Date:  2014-09-15       Impact factor: 32.976

6.  Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients.

Authors:  Daniella Klebaner; Stephen Hamilton-Dutoit; Thomas Ahern; Anatasha Crawford; Thomas Jakobsen; Deirdre P Cronin-Fenton; Per Damkier; Emiel Janssen; Anders Kjaersgaard; Anne Gulbech Ording; Håvard Søiland; Henrik Toft Sørensen; Timothy L Lash; Ylva Hellberg
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

7.  Design and Development of an Intelligent Clinical Decision Support System Applied to the Evaluation of Breast Cancer Risk.

Authors:  Manuel Casal-Guisande; Alberto Comesaña-Campos; Inês Dutra; Jorge Cerqueiro-Pequeño; José-Benito Bouza-Rodríguez
Journal:  J Pers Med       Date:  2022-01-27

8.  Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study.

Authors:  S Walters; C Maringe; J Butler; B Rachet; P Barrett-Lee; J Bergh; J Boyages; P Christiansen; M Lee; F Wärnberg; C Allemani; G Engholm; T Fornander; M L Gjerstorff; T B Johannesen; G Lawrence; C E McGahan; R Middleton; J Steward; E Tracey; D Turner; M A Richards; M P Coleman
Journal:  Br J Cancer       Date:  2013-02-28       Impact factor: 7.640

9.  Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.

Authors:  T L Lash; L Pedersen; D Cronin-Fenton; T P Ahern; C L Rosenberg; K L Lunetta; R A Silliman; S Hamilton-Dutoit; J P Garne; M Ewertz; H T Sørensen
Journal:  Br J Cancer       Date:  2008-07-29       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.